- Home
- QCRH vs STOK Comparison
QCRH vs STOK Comparison
Compare QCRH & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- STOK
- Stock Information
- Founded
- QCRH 1993
- STOK 2014
- Country
- QCRH United States
- STOK United States
- Employees
- QCRH 1013
- STOK N/A
- Industry
- QCRH Major Banks
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- QCRH Finance
- STOK Health Care
- Exchange
- QCRH Nasdaq
- STOK Nasdaq
- Market Cap
- QCRH 1.3B
- STOK 1.3B
- IPO Year
- QCRH 1993
- STOK 2019
- Fundamental
- Price
- QCRH $78.95
- STOK $30.30
- Analyst Decision
- QCRH Buy
- STOK Strong Buy
- Analyst Count
- QCRH 4
- STOK 9
- Target Price
- QCRH $90.00
- STOK $31.00
- AVG Volume (30 Days)
- QCRH 87.1K
- STOK 1.1M
- Earning Date
- QCRH 10-22-2025
- STOK 11-04-2025
- Dividend Yield
- QCRH 0.31%
- STOK N/A
- EPS Growth
- QCRH 3.93
- STOK N/A
- EPS
- QCRH 7.15
- STOK 0.68
- Revenue
- QCRH $336,623,000.00
- STOK $205,632,000.00
- Revenue This Year
- QCRH N/A
- STOK $416.54
- Revenue Next Year
- QCRH $18.11
- STOK N/A
- P/E Ratio
- QCRH $11.00
- STOK $44.35
- Revenue Growth
- QCRH N/A
- STOK 1128.17
- 52 Week Low
- QCRH $60.83
- STOK $5.35
- 52 Week High
- QCRH $96.08
- STOK $38.69
- Technical
- Relative Strength Index (RSI)
- QCRH 60.22
- STOK 59.76
- Support Level
- QCRH $74.91
- STOK $27.53
- Resistance Level
- QCRH $78.82
- STOK $29.38
- Average True Range (ATR)
- QCRH 2.01
- STOK 2.02
- MACD
- QCRH 0.15
- STOK 0.43
- Stochastic Oscillator
- QCRH 82.17
- STOK 96.19
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.